The Goldman Sachs Group Initiates Coverage on City Therapeutics (NASDAQ:CTY)

Posted by Stacy Sanders on Nov 10th, 2026

Research analysts at The Goldman Sachs Group initiated coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm set an “early-stage biotech” rating on the stock.

CTY has been the topic of a number of other reports. Oppenheimer assumed coverage on shares of City Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $46.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of City Therapeutics in a research note on Tuesday. They set a “buy” rating and a $32.00 price objective for the company. Finally, Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a research report on Saturday, October 24th. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $37.33.

Read Our Latest Stock Report on CTY

City Therapeutics Stock Performance

CTY opened at $18.67 on Tuesday. City Therapeutics has a 1 year low of $15.81 and a 1 year high of $23.88.

Insider Buying and Selling at City Therapeutics

In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of the stock in a transaction on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the acquisition, the insider owned 13,692,507 shares in the company, valued at $246,465,126. The trade was a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert Nelsen purchased 170,000 shares of the stock in a transaction on Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This represents a 1.26% increase in their position. The SEC filing for this purchase provides additional information.